Genscript Biotech Share Price Plummets Despite Positive Trial Results from Associate Company

Stock News06-15

Shares of Genscript Biotech (01548) experienced a sharp decline, dropping more than 10% at one point during the trading session.

At the time of writing, the stock was down 8.37% to HK$11.93, with a trading turnover reaching HK$295 million.

The market movement follows an announcement from the company's associate firm, Legend Biotech, regarding initial clinical proof-of-concept data for its investigational in vivo CD19/CD20 dual-target CAR-T cell therapy, LB2501, for patients with relapsed/refractory B-cell non-Hodgkin lymphoma.

These findings were presented at the latest breakthrough session of the 2026 European Hematology Association Congress.

In an ongoing Phase I study, patients with R/R B-NHL who received a single infusion achieved a 100% objective response rate and an 83.3% complete response rate at the second dose level.

All responses were reported to be ongoing at the time of the data cutoff.

The therapy also demonstrated a favorable safety profile, with no reports of dose-limiting toxicities, serious adverse events, immune effector cell-associated neurotoxicity syndrome, or deaths.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1182202989?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-15 11:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1182202989","market":"hk","top_or_hot":-1,"title":"Genscript Biotech Share Price Plummets Despite Positive Trial Results from Associate Company","media":"Stock News","content":"<p>Shares of <b>Genscript Biotech</b> (<b>01548</b>) experienced a sharp decline, dropping more than 10% at one point during the trading session.<br><br>At the time of writing, the stock was down 8.37% to HK$11.93, with a trading turnover reaching HK$295 million.<br><br>The market movement follows an announcement from the company's associate firm, <b>Legend Biotech</b>, regarding initial clinical proof-of-concept data for its investigational in vivo CD19/CD20 dual-target CAR-T cell therapy, LB2501, for patients with relapsed/refractory B-cell non-Hodgkin lymphoma.<br><br>These findings were presented at the latest breakthrough session of the 2026 European Hematology Association Congress.<br><br>In an ongoing Phase I study, patients with R/R B-NHL who received a single infusion achieved a 100% objective response rate and an 83.3% complete response rate at the second dose level.<br><br>All responses were reported to be ongoing at the time of the data cutoff.<br><br>The therapy also demonstrated a favorable safety profile, with no reports of dose-limiting toxicities, serious adverse events, immune effector cell-associated neurotoxicity syndrome, or deaths.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Genscript Biotech Share Price Plummets Despite Positive Trial Results from Associate Company</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGenscript Biotech Share Price Plummets Despite Positive Trial Results from Associate Company\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-06-15 11:26</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of <b>Genscript Biotech</b> (<b>01548</b>) experienced a sharp decline, dropping more than 10% at one point during the trading session.<br><br>At the time of writing, the stock was down 8.37% to HK$11.93, with a trading turnover reaching HK$295 million.<br><br>The market movement follows an announcement from the company's associate firm, <b>Legend Biotech</b>, regarding initial clinical proof-of-concept data for its investigational in vivo CD19/CD20 dual-target CAR-T cell therapy, LB2501, for patients with relapsed/refractory B-cell non-Hodgkin lymphoma.<br><br>These findings were presented at the latest breakthrough session of the 2026 European Hematology Association Congress.<br><br>In an ongoing Phase I study, patients with R/R B-NHL who received a single infusion achieved a 100% objective response rate and an 83.3% complete response rate at the second dose level.<br><br>All responses were reported to be ongoing at the time of the data cutoff.<br><br>The therapy also demonstrated a favorable safety profile, with no reports of dose-limiting toxicities, serious adverse events, immune effector cell-associated neurotoxicity syndrome, or deaths.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HK0000306701.USD","symbol_name":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) INC","start_time":0,"source_url":"","article_id":"1182202989","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1182202989","pubTimestamp":1781493984,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Shares of Genscript Biotech (01548) experienced a sharp decline, dropping more than 10% at one point during the trading session.At the time of writing, the stock was down 8.37% to HK$11.93, with a...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HK0000306701.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) INC","HK0000320223.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) ACC","BK1583":"高瓴概念","HK0000320264.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) ACC","LEGN":"传奇生物","BK1141":"生命科学工具和服务","VXUS":"国际股票ETF-Vanguard","BK1576":"医药外包概念","01548":"金斯瑞生物科技","BK4588":"碎股","BK4585":"ETF&股票定投概念","HK0000306685.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) INC","BK4505":"高瓴资本持仓","BK4139":"生物科技"},"translate_title":"尽管联营公司试验结果积极，金斯瑞生物科技股价仍暴跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01548":1,"VXUS":1,"LEGN":1},"content_text":"Shares of Genscript Biotech (01548) experienced a sharp decline, dropping more than 10% at one point during the trading session.At the time of writing, the stock was down 8.37% to HK$11.93, with a trading turnover reaching HK$295 million.The market movement follows an announcement from the company's associate firm, Legend Biotech, regarding initial clinical proof-of-concept data for its investigational in vivo CD19/CD20 dual-target CAR-T cell therapy, LB2501, for patients with relapsed/refractory B-cell non-Hodgkin lymphoma.These findings were presented at the latest breakthrough session of the 2026 European Hematology Association Congress.In an ongoing Phase I study, patients with R/R B-NHL who received a single infusion achieved a 100% objective response rate and an 83.3% complete response rate at the second dose level.All responses were reported to be ongoing at the time of the data cutoff.The therapy also demonstrated a favorable safety profile, with no reports of dose-limiting toxicities, serious adverse events, immune effector cell-associated neurotoxicity syndrome, or deaths.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1182202989","isCrawlerRequest":true}